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Abstract 
Proteolytic cascades are deeply involved in critical stages of cancer progression. During the 
course of peptide-wise analysis of shotgun proteomic datasets representative of colon 
adenocarcinoma (AC) and ulcerative colitis (UC), we detected a cancer-specific proteolytic 
fingerprint composed of a set of numerous protein fragments cleaved C-terminally to V, I, A, 
T, or C residues, significantly overrepresented in AC. A peptide set linked by a common VIATC 
cleavage consensus was the only prominent cancer-specific proteolytic fingerprint detected. 
This sequence consensus indicated neutrophil elastase as a source of the fingerprint. We also 
found that a large fraction of affected proteins are RNA processing proteins associated with 
the nuclear fraction and mostly cleaved within their functionally important RNA-binding 
domains. Thus, we detected a new class of cancer-specific peptides that are possible markers 
of tumor-infiltrating neutrophil activity, which often correlates with the clinical outcome. Data 
are available via ProteomeXchange with identifiers: PXD005274 (Dataset 1) and PXD004249 
(Dataset 2). Our results indicate the value of peptide-wise analysis of large global proteomic 
analysis datasets as opposed to protein-wise analysis, in which outlier differential peptides 
are usually neglected.   
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Introduction 
Cancer-specific proteolytic activity is one of the highlights of cancer progression, and specific 
changes in the tumor degradosome may serve as a reservoir for potential diagnostic molecular 
features (1). For example, cancer-specific fragments of cytokeratins are among the most 
frequently tested protein-based cancer markers. Cytokeratin typing and quantitation for 
cancer studies, as well as diagnosis, prognosis, and therapy monitoring, have become routine 
in recent years (2), (3), (4), (5), (6). Moreover, keratins are cleaved in a cancer-dependent 
manner, and some of the keratin-based antibodies used in the context of cancer recognize 
such fragments (7). For instance, keratins 18 and 19 are known substrates for caspase 
degradation (8) which occurs in the intermediate stage of apoptosis (6), when well-controlled 
proteolysis of many components of the cytoplasmic and nuclear cytoskeleton orchestrates 
cellular breakdown. The resulting abundant keratin fragments are released into the circulation 
by tumor cells and can be detected there. Currently, several antibodies with epitopes linked 
to keratins and/or their fragments, such as tissue polypeptide antigen (TPA), tissue 
polypeptide-specific antigen, keratin 19 fragment (Cyfra21-1), and keratin 18 fragment (M30, 
M65), are widely used for cancer studies, and their clinical value is frequently assessed by 
numerous groups in different experimental settings. In the case of certain carcinomas, such 
as non-small cell lung cancer (6), oral cancer (7), bladder cancer (BC) (9), and colon cancer (10), 
serum assays derived from keratins 8, 18, and 19 are increasingly used to monitor tumor load 
and disease progression and for the early detection of recurrence and fast assessment of the 
efficacy of the response to therapy (11). In addition, tumors derived from epithelial cells are 
known to retain the cytokeratin expression pattern characteristic of the originating cell types, 
development, and differentiation stage (12), (13). Thus, the cytokeratin profile is indicative of 
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a tumor’s origin and generally retained, even in mobilized cells far from the primary source of 
malignancy.  
However, knowledge regarding the proteolytic fragments populating the plasma/ serum/ 
urine/ saliva of cancer patients is very limited. A plethora of commercially available antibodies, 
in general of not precisely defined affinities, are used to explore the potential of protein 
fragments as cancer markers. Such a “black-box” approach lacks a precise definition of targets 
and is carried out without selection of the best fragments. In addition, antibody-based 
approaches suffer from cross-reactivity with other targets, leading to numerous controversies, 
as for instance raised in the case of keratin-based markers (14), (15), (16). Although cross-
reactivity decreases the specificity of existing tests, many currently available kits have 
reasonable levels of sensitivity and specificity. Assessment of the true sensitivity and 
specificity of cytokeratin fragment-based tests, excluding cross-reactivity phenomena, would 
require the application of more selective methods, such as methods based on mass 
spectrometry. To the best of our knowledge, these approaches have not yet been attempted.  
In the present study, we re-analyzed the datasets collected during global proteomic studies of 
adenocarcinoma (AC) and ulcerative colitis, using data obtained previously by our group (17) 
and those available from the MS-data PRIDE repository (18), focusing on disease-specific 
proteolytic events. In addition to detecting peptides resulting from the caspase cleavage of 
keratins in AC, we identified other disease-specific proteolytic cleavages in a wider set of 
proteins. In some cases, the resulting peptides are an order of magnitude more abundant in 
cancer than in control non-cancerous tissue, whereas the abundance ratio for a caspase-
cleaved keratin 18 peptide is only 3. The cleavage pattern of peptides detected in cancer tissue 
revealed a strong preference for V, I, A, T, and C residues at the P1 cleavage site (VIATC 
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consensus), making neutrophil elastase the most probable candidate for the protease 
responsible for the observed cancer-specific cleavage. In result, by re-analysing the existing 
datasets we identified a new class of cancer-specific protein fragments that are potential 
markers of the presence and progression of cancer.  
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Experimental Procedures 
Experimental design and Statistical Rationale 
In the presented study four distinct datasets have been processed, as summarized in Table 1 
and Scheme 1, namely: Dataset 1 - iTRAQ differential proteomic datasets obtained during the 
course of global proteomic analyses of tubulovillous adenoma (TVA), tubular adenoma (TA), 
and AC tissue (17) – data deposited in PRIDE archive: PXD005274. Dataset 2 - the results of 
label free proteomic analysis of bladder cancer and colon cancer tissues - data deposited in 
PRIDE archive: PXD004249. Dataset 3 - data deposited in the proteomic data repository PRIDE, 
comprising 32 LC-MS raw files derived from 16 samples of colon cancer tissue and 16 healthy 
donor samples uploaded by the CPTAC consortium (PRIDE archive identifiers PXD002041 – 
PXD002050), selected at random from the larger available dataset and Dataset 4 - data 
deposited in the proteomic data repository PRIDE, comprising 20 LC-MS raw files originating 
from the analysis of endoscopic mucosal colon biopsies from non-inflamed tissue in 10 
patients with UC and 10 controls (PRIDE archive identifier PXD001608). For each of the four 
datasets different approach to data analysis was used, as described below:  
Dataset 1 - Re-analysis of iTRAQ labelled proteome of tumor tissues. 
Raw datasets of iTRAQ labelled proteomes of tubulovillous adenoma (TVA), tubular adenoma 
(TA), and AC tissue were obtained as described previously (17). The mass spectrometry 
proteomics data for Dataset 1 have been deposited to the ProteomeXchange Consortium via 
the PRIDE (19) partner repository with the dataset identifier PXD005274 and 
10.6019/PXD005274. For the re-analysis a two-step procedure was applied. First, MS/MS 
spectra were extracted from raw files using Mascot Distiller (v 2.4.1, Matrix Science), followed 
by an initial Mascot (v. 2.4.1, Matrix Science) database search restricted to human sequences 
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against the SwissProt database (release 10_2012, 20 232 entries actually searched). Search 
parameters were: enzyme specificity -  trypsin; number of missed cleavage sites - 1; precursor 
tolerance window - 30 ppm; MS/MS tolerance - 0.2 Da; variable modification - methionine 
oxidation; fixed modification - cysteine carbamidomethylation, labelling method - iTRAQ 4-
plex. Mascot search results were exported as *.dat files and subsequently internally calibrated 
using in house DatViewer software procedure described in  Supplementary Method 1 in ref. 
(20). In short, the internal calibration procedure implemented in the DatViewer software used 
differences between observed and theoretical m/z values of precursor and fragment ions for 
a subset of high quality spectra selected from the peptide list obtained during an initial Mascot 
search to calculate systematic m/z measurement errors. Identifications with scores above 
both homology and identity thresholds in the initial search were used as an inclusion criterion 
for reference calibration list. A linear relationship between m/z value and measurement error 
was assumed and robust least squares method was used for fitting the calibration curve. The 
value of a systematic error calculated for a given m/z range was then subtracted from 
measured m/z values of all ions.  Ion m/z tolerances were calculated separately for each 
sample based on standard deviation of m/z error of reference list peptides after calibration. 
Tolerance values were set for the next round of database search at 3 and 5 standard deviations 
for precursor and fragment ions, respectively. Calibrated spectra with sample-specific mass 
tolerance values were saved as mass-error corrected *.mgf files. Preliminary search results 
were discarded after this step and in a second step a new database search was performed on 
calibrated data, again using Mascot search engine, with nearly the same search parameters, 
except enzyme specificity which was set to “no enzyme specificity” and sample specific mass 
tolerance values.  Also, in the second database search, target-decoy search strategy was 
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applied to estimate the FDR of resulting identifications, and the quantitative analysis was 
carried out only using a set of peptides which fulfilled the criterion of FDR < 1%. Individual 
peptide abundance AC/NC ratios were normalized by their corresponding AC/NC protein 
ratios. Peptides and proteins identified are listed in Supporting Material Table S4. 
Dataset 2 - Quantitative analysis of colon cancer  and bladder cancer  tissue samples using 
label-free method  
Patient selection. Clinical tissue samples were collected at the Maria Sklodowska-Curie 
Memorial Cancer Center as described previously (21). The study protocol was approved by the 
Cancer Center Bioethics Committee, and all patients provided signed informed consent before 
inclusion. Samples of malignant tissue and adjacent healthy tissue were obtained after surgical 
resection. The tissue samples were immediately snap-frozen in liquid nitrogen and stored at -
72 °C until use. 
Proteome extraction. Tissue samples were vigorously washed with cold phosphate buffered 
saline (PBS) containing protease (Roche) and phosphatase inhibitors (Sigma) to remove 
residual blood and then centrifuged at 15,000 × g at 4 °C for 3 min. Proteins were extracted 
using the ProteoExtract® Subcellular Proteome Extraction Kit (Calbiochem, Cat. No. 539790) 
according to the manufacturer’s protocol. The protein concentration was measured using the 
Bradford method. These fractions were stored as aliquots at -72 °C until use. 
Protein sample preparation. Proteins were precipitated from equal amounts (by protein 
content) of sample from each tissue type using the ProteoExtract Protein Precipitation Kit 
(Calbiochem) according to the manufacturer’s protocol. Protein pellets were resuspended in 
200 μl of dissolution buffer (0.5 M triethylammonium bicarbonate with 0.1% SDS). To facilitate 
protein solubilization, samples were vortexed thoroughly and (optionally) treated with five 
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pulses from a 500W Cole-Parmer ultrasonic homogenizer (amp. 24%, pulse 2 s, gap 2 s). The 
protein concentrations of the combined and subcellular samples were measured using the 
Bradford method. Aliquots of samples (100 g) were stored at -72 °C. 
LC-MS settings. Peptides mixtures were analyzed by LC-MS (liquid chromatography coupled 
to tandem mass spectrometry) using Nano-Acquity (Waters) LC system and Orbitrap Velos 
mass spectrometer (Thermo Electron Corp., San Jose, CA). Prior to the analysis, proteins were 
subjected to standard ”in-solution digestion” procedure during which proteins were reduced 
with 200 mM dithiothreitol (for 60 minutes at 60 °C), alkylated with 500 mM iodoacetamide 
(45 minutes in dark at room temperature) and digested overnight with trypsin (sequencing 
Grade Modified Trypsin - Promega V5111). Peptide mixture was applied to RP-18 precolumn 
(nanoACQUITY Symmetry® C18 – Waters 186003514) using water containing 0.1 % TFA as 
mobile phase and then transferred to nano-HPLC RP-18 column (nanoACQUITY BEH C18 - 
Waters 186003545) using an acetonitrile gradient (5 % - 35 % AcN in 180 minutes) in the 
presence of 0.05 % formic acid with the flowrate of 250 nl/min. Column outlet was directly 
coupled to the ion source of the spectrometer. A blank run ensuring lack of cross 
contamination from previous samples preceded each analysis. 
Qualitative analyses (i.e. peptide and protein identification) were performed on pooled 
samples in data-dependent MS-to-MS/MS acquisition mode. Up to five MS/MS processes 
were allowed for each MS scan. To increase the number of peptide identifications, three LC-
MS/MS runs were performed per pooled sample, each covering one of three ranges of m/z 
values: 300–600, 500–900, or 800–2000. This approach substantially improved the number of 
peptides. Quantitative analyses of individual samples were carried out in separate survey scan 
LC-MS runs with an m/z measurement range of 300-2000 using the same acetonitrile gradient 
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as in the qualitative LC-MS/MS runs. The data-dependent MS-to-MS/MS switch was disabled, 
and the spectrometer resolution was set to 15 000. 
Qualitative MS data processing and database search. Qualitative MS data processing and a 
database search were carried out as described for iTRAQ-labeled data (ref. (17) and above), 
but with the following differences in search parameters: fixed modification, 
carbamidomethylation (C); variable modifications, oxidation (M). Only peptide spectrum 
matches with q-values ≤ 0.01 were considered to be confidently identified. Proteins identified 
by a subset of peptides from another protein were excluded from the analysis, and proteins 
matching the same set of peptides were clustered into single groups. Peptides and proteins 
identified are listed in Supporting Material Table S4. The mass spectrometry proteomics data 
have been deposited to the ProteomeXchange Consortium via the PRIDE (19) partner 
repository with the dataset identifier PXD004249 and 10.6019/PXD004249. 
Quantitative MS data processing. The list of peptides identified from the LC-MS/MS runs was 
overlaid onto two-dimensional maps generated from the LC-MS profile data for individual 
samples. A more detailed description of the feature extraction procedure is provided 
elsewhere (22). Briefly, the list of identified peptides was used to tag the corresponding 
peptide-related ion spectra on the basis of m/z value, the deviation from the predicted elution 
time, and the match between theoretical and observed isotopic envelopes. The relative 
abundance of each peptide ion was determined as the volume of the corresponding peak. To 
minimize the effects of non-biological sources of variation, log-transformed peptide 
abundance was normalized by fitting a robust, locally weighted regression smoother (LOESS) 
between the individual samples and a median pseudosample. The parameters of the fit were 
established using a set of features exhibiting low variance in the non-normalized data and 
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then applied to the whole dataset. For protein-wise analysis, the normalized peptide-level 
data were rounded up to relative protein abundance. The procedure involved rescaling the 
abundance of peptides originating from the same protein to a common level and computing 
their median value. 
Statistical analysis of quantitative MS results. The Mann-Whitney U-test was used to select 
differentially expressed proteins. The resulting p-values were corrected for multiple 
hypothesis testing using the Benjamini–Hochberg step-up procedure, which controls for the 
false discovery rate (23). Relative peptide abundances with adjusted p-values ≤ 0.05 were 
considered significantly changed in at least one of the studied groups. All statistical analyses 
were performed using a combination of proprietary software running in the MATLAB 
environment (MathWorks; MStat, available at http://proteom.ibb.waw.pl) and in-house 
scripts for tasks such as identifying cleavage type from peptide and protein sequence or data 
format conversion. 
Datasets 3  and 4 - Re-analysis of PRIDE datasets 
For the analysis of PRIDE data, the extraction of MS/MS spectra was carried out, followed by 
an initial Mascot (v. 2.4.1, Matrix Science) database search restricted to human sequences 
against the UniProt database (release 06_2015, 68 554 entries searched). Search parameters 
were: enzyme specificity - trypsin; number of missed cleavage sites - 1; precursor tolerance 
window - 30 ppm; MS/MS tolerance - 0.2 Da; variable modification - methionine oxidation; 
fixed modification - cysteine carbamidomethylation. Mascot search results were exported as 
*.dat files and internally calibrated using  the same procedure as in the case of iTRAQ data, 
and saved as mass-error corrected *.mgf files with sample specific mass tolerance. The 
second, refined, database search was carried out using the MS-GF+ (v. 9979) (24) search 
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engine against the Uniprot database restricted to human sequences. Search parameters were: 
mass tolerances calculated individually for each sample; enabled decoy search; no enzyme 
specificity; fixed modification - cysteine carbamidomethylation; variable modifications 
defined as methionine oxidation, N-terminal acetylation, and glutamine substitution by pyro-
Glu. Following the extraction of peptides fulfilling the criterion of FDR< 1%, (peptides and 
proteins identified are listed in Supporting Material Table S4) the quantitative analysis was 
carried out using a “spectral count” approach (25).  
 
Results 
Previously, we conducted a global proteomic analysis of iTRAQ labelled AC, TVA, and TA tissue 
in comparison to tumor-adjacent tissue (17). In this approach, pooled trypsin-digested iTRAQ-
labeled samples were fractionated by isoelectrofocusing and then subjected to LC-MS (IEF-LC-
MS approach) – Dataset 1. Based on the stringent selection of iTRAQ-labeled peptides with 
q<0.01, we established a list of proteins significantly over- or under-represented in the AC 
proteome. The list includes for instance keratins 8 and 20, significantly downregulated in 
cancer, but not keratin 18. However, during the subsequent peptide-wise analysis of the same 
datasets, we noted the presence of a large subset of peptides regulated in a markedly different 
way than the other peptides originating from the same proteins. The commonality in these 
peptides was the presence of non-tryptic cleavage sites. In Figure 1 we present the AC/NC 
peptide-wise ratios (fold change, FC) calculated by the analysis of iTRAQ signals (tag 117 for 
AC, tag 114 for NC) for all peptides from keratin 8 and keratin 18 detected in three replicates 
of the experiment. Keratin 18 (Figure 1A) tryptic peptides are characterized by an AC/NC ratio 
close to 1, in agreement with a lack of change in the K18 level detected during the protein-
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wise analysis. On the other hand, several outliers are present (colored circles), all resulting 
from non-tryptic cleavage. Some of the outlier peptides were characterized by large FC values, 
some even exceeding 10, reproducibly in all three experiments. This finding indicates that 
these peptides are up to an order of magnitude more abundant in AC than NC samples. 
Caspases 3, 7, and 9 are known to cleave keratin 18 in a cancer-specific way, and caspase-
cleaved keratin 18 fragments are established cancer biomarkers (26). Indeed, two keratin 18 
peptides derived from caspase cleavage were found in our dataset: Q225AQIASSGLTVEVD238 
with FC>3 and N391LGDALD397 with FC=1.5. These peptides are “semi-tryptic”, as the sample 
was subjected to tryptic cleavage preceding LC-MS and the caspase cleavage site is 
accompanied by a tryptic cleavage site at the other end of the peptide. However, stronger 
outliers with larger FC values represent other peptides cleaved at different, non-caspase 
sequence motifs. Cleaved sequences in these keratin 18 peptides include (P1-P1’ positions) 
Ser-Ser, Ser-Thr, Val-Thr, Thr-Gln, Gly-Asp, and Ile-Gln. The strongest overrepresented 
cleavage occured at Val-Thr (FC>10), resulting in three detected peptides, one containing P1 
residue (V282) and two containing P1’ (T283) residue. All three of them are overrepresented in 
AC to varying degrees. Underrepresented cleavages were also found, with the most 
underrepresented peptide pair resulting from non-tryptic cleavage at the Gly393-Asp site. The 
non-tryptic cleavage sites localize to three regions of keratin 18: linker L12, the tail, and the 
N-terminal part of coil 2B, which are known to be unstructured in keratin filaments (27). 
Numerous non-tryptic sites characterized by a large AC/NC ratio were also found in keratin 8 
(Figure 1B). The upregulation of these peptides contrasts with the downregulation of keratin 
8 in AC vs. NC samples, which is reflected by the median ratio of tryptic peptides of 0.5. Non-
tryptic cleavages with FC values as large as 10 occurred in five regions of the protein, including 
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the unstructured head, linker L12, and an interface between linker L2 and coil 2B. 
Interestingly, the majority of non-tryptic cleavages in both keratins occurred C-terminal to Val 
or Ile. 
To explore this observation in a more systematic manner we listed all non-tryptic cleavage 
sites in the whole dataset of 17,965 peptides, corresponding to 4,254 proteins, and calculated 
their abundance AC/NC ratios, normalized by their corresponding AC/NC protein ratios. Next, 
we calculated the median AC/NC ratio for each type of amino acid at positions P4…..P4’ of the 
cleavage site. Though no preference was detected for a particular amino acid type at positions 
P2, P1’, P2’ (Figure 2) and also P4’, P3’, P3, and P4 (data not shown) Mann-Whitney U-test 
indicated a significant overrepresentation (p value < 10-6) of peptides cleaved after Val, Ile, 
Ala, Thr, or Cys (P1 position) in cancer samples. Hereafter, this is referred to as the VIATC 
consensus. In contrast, peptides cleaved after Trp or Glu generally had a lower ratio in cancer. 
Of the 180 strongly (FC>4) upregulated non-tryptic peptides identified, 176 bear the VIATC 
consensus at the P1 cleavage site. A total of 456 VIATC peptides were found in the whole 
dataset, so 38% of VIATC peptides are strongly upregulated (FC>4) in AC. Exemplary 
fragmentation spectra of VIATC peptides are shown in Supplementary Material Figure S1. 
This analysis provides a strong indication that cleavage at a VIATC consensus in a large number 
of proteins is a much more frequent event in AC tissue than in normal tissue. We analyzed all 
cleavage sites within the MEROPS (28) and PMAP-CutDB (29) databases to find proteases 
characterized by the P1 VIATC consensus and lack of preferences at other positions. Our 
analysis indicated neutrophil elastase (NE), a serine protease (S01.131) known to cleave 
collagen and elastin, as the only protease to strictly fulfill these criteria. In the MEROPS 
database, the NE consensus for P4 - P4' positions is defined as -/-/-/viat -/-/-/- , indicating a 
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nearly exact match to the VIATC consensus at P1 and agreement with a lack of preference at 
other positions. Among 488 NE cleavage sites collected in the MEROPS database, 392 (80%) 
match the VIATC consensus (P1: Ile (n=142), Val (n=129), Ala (n=61), Thr (n=56), Cys (n=4)). 
Other proteases cleaving at a VIATC consensus have much broader specificities and could not 
explain the results shown in Figure 2. We concluded that NE is the most probable candidate 
for the cancer-specific proteolytic activity detected in AC samples. 
Next, we investigated proteins undergoing cancer-dependent cleavage at VIATC consensus 
sites in AC. From 456 VIATC peptides in the dataset, we selected peptides with FC>4 that were 
detected in at least two of the three experiments. This narrowed down the set of peptides to 
170 originating from 118 proteins (Supplementary Material Table S1). Analysis of this protein 
set by STRING (30) (Figure 3) revealed significant interconnections between a majority of these 
proteins. Cell component gene ontology analysis in STRING showed significant 
overrepresentation of proteins annotated to focal adhesion, the endoplasmic reticulum (ER) 
lumen, mitochondrion, and ribonucleoprotein complex. The group of ER lumen proteins 
contained four collagens, and a set of 10 heterogeneous nuclear ribonucleoproteins (hnRNPs) 
was prominent among the ribonucleoprotein complex proteins.  
We also re-analyzed differential proteomic experiments of AC tissue fractionated into 
cytoskeleton, cytoplasmic, membrane + organelle, and nuclear fractions based on the total 
dataset of 52,007 peptides (q<0.01) (17). The analysis of VIATC cut sites in fractionated AC 
samples (with total of 5,170 peptides bearing a VIATC consensus) revealed much fewer 
number of such peptides in the cytoskeletal fraction than in the remaining fractions (Figure 
4A). In addition, we observed a prominent cancer-specific increase in the abundance of VIATC 
consensus peptides only in the nuclear fraction (average 2.5-fold increase in AC than NC 
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control; Figure 4B). In the three other fractions, including cytoskeleton, the increase in the 
abundance of VIATC peptides was much less pronounced or insignificant. In the cytoskeleton 
VIATC peptides are markedly less common than in other fractions, and cancer-dependent 
cleavage, as observed with keratins, is an exception rather than a rule. In contrast, in the 
nuclear fraction the abundance of a majority of the VIATC peptides was cancer-dependent; 
thus in this case VIATC cleavage en gros may depend strongly on the presence of cancer. In 
the nuclear fraction, 628 VIATC peptides had an AC/NC ratio >4 (Supplementary Material Table 
S1). These peptides belonged to 398 proteins (nucVIATC proteins) that could be classified into 
a few major groups, mainly representing proteins engaged in pre-mRNA processing, mRNA 
transport, and chromatin modifications, many of them were found in the unfractionated 
sample analysis (Figure 3), including a group of nine hnRNPs, out of 16 major known hnRNPs. 
These proteins were accompanied in the nucVIATC set by 75 other proteins categorized as 
RNPs by the gene ontology algorithm (Supplementary Material Table S1). Thus, a large fraction 
(75/398) of nucVIATC proteins are RNPs. In the nucVIATC set, a large number of proteins were 
also classified as ribosome assembly proteins, likely originating from pre-ribosomal 
nuclear/nucleolar intermediates (31). We also noted the presence of numerous mitochondrial 
proteins, possibly originating from the contamination of nuclear protein preparations, 
indicating that the overrepresentation of RNPs in the nuclear set is even more pronounced. 
Of these 75 RNPs, 22 contain RRM RNA-binding domains. Interestingly, of the 35 VIATC cut 
sites observed in these 22 proteins, 28 (80%) are located within RRM domains and 7 outside 
these domains. RRM domains cover approximately 30% of the amino acid sequences of these 
22 proteins; therefore, in the case of random proteolysis, the expected cleavage frequency 
within RRM domains should not exceed 30%. This finding indicates a strong preference for 
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VIATC cleavage within RRM domains. The rationale for selective cleavage of RRM domains is 
not straightforward. These domains may be less structured in solution than the remaining 
regions. Also, RRM domains are cleaved with strong preference for Val or Ile (26 cleavage 
sites) compared to Thr, Ala, or Cys (2 cleavage sites) (Supplementary Material Table S2). 
Moreover, 21 of the 28 cut sites inside RRM domains were located within known secondary 
structure motifs (helices or sheets).  
Of seven sites localized outside RRM domains, five were located in Asp/Glu rich 
regions: two in the helical leucine zipper oligomerization domain spanning positions 194-216 
of hnRNP C1/C2 (32) critical for RNA-binding activity, and three in the C-terminal flanking 
smart00582 nuclear pre-mRNA regulation domain spanning positions 689-746 of U2 snRNP-
associated SURP motif-containing protein. Another cleavage outside RRM domains affects the 
flanking region of the PWI RNA/DNA binding domain of RNA-binding protein 25. The PWI 
domain regulates Bcl-x-pre-mRNA alternative splicing and its flanking domain serves as a 
binding partner; thus, it participates in directing Bcl to either its pro-apoptotic Bcl-xS or anti-
apoptotic Bcl-xL form, with profound consequences on cell fate (33). Therefore, the observed 
proteolytic activity is not an indiscriminate cleavage of cellular debris, but was executed on 
proteins in their native state and overwhelmingly affected functionally important domains.  
Next, we investigated whether cancer-specific VIATC cleavage peptides allow 
differentiation of TVA and TA samples (labeled with iTRAQ 115 and 116, respectively) from NC 
and/or AC samples (17). The abundance of VIATC-cleaved peptides in TVA and TA samples 
compared to AC is shown in Figure 5A. The average TVA/NC and TA/NC ratios for VIATC did 
not shift from 1 (TVA) or were much smaller than the AC/NC ratio (TA). Generally, cleavage at 
VIATC in TVA and TA seemed to be disease-independent, in contrast to AC. Principal 
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component analysis based on all VIATC peptides (Figure 5B) revealed that TVA and TA states 
were not well separated from NC controls in the dimension of the first component. However, 
TVA and TA were well separated from NC controls in the dimension of the second component. 
The analysis of a set of peptides leading to this separation revealed consistently that, for 
example, keratin 19 peptide ASDGLAGNEK (Supplementary Material Figure S2) was less 
abundant in TA and TVA than NC or AC samples. Many more non-tryptic peptides with large 
FC values, differentiating TVA and TA from NC controls, were found in a set of other (non-
VIATC) non-tryptic peptides (Supplementary Material Table S3). An overall downregulation of 
other non-tryptic cleavages in TVA and TA (Figure 5A) was noted. This set is exemplified by 
cleavage at Gly-Asp in keratin 18, already mentioned in the analysis of K18 peptides at (Figure 
1) as most downrepresented in AC. As shown in Supplementary Material Figure S3, the 
peptides LLEDGEDFNLG- and -DALDSSNSMQTIQK resulting from cleavage at this site were 
much less abundant not only in AC, but also TVA and TA compared to NC controls. 
Interestingly, the Gly-Asp site in keratin 18 is known to be cleaved by meprin beta protease 
(34). Meprin beta is expected to be co-expressed with meprin alpha in the small intestine, but 
not the colon (35). However, we detected both proteins in colon tissue, and both were found 
to be much more abundant in normal tissue than in TVA, TA, or AC (17). Meprin alpha 
(Q16819) and beta (Q16820) are interdependent proteases involved in tumor progression in 
colon cancer (36) and are expected to be upregulated in tumors, in contrast to the observed 
downregulation of their putative cleavage products in the present study. Such interesting 
cases require further studies, as no commonality was found to link this set of peptides. 
However, when all non-tryptic peptides were taken into account, principal component 
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analysis (Figure 6) revealed a significant separation of TA and TVA samples from NC samples 
along the first component axis.  
The results of Dataset 1 presented above are based on analyses of pooled samples 
obtained by mixing tissue samples collected from different patients (17). Pooling allowed for 
in-depth analysis and access to quantitative information on low-abundance peptides/proteins 
at the cost of a decreased number of replicate experiments. Therefore, we analyzed a set of 
40 independently collected tumor tissue/control samples using a label-free quantitation single 
pass LC-MS/MS approach. In the new set, 10 samples originated from a colon tumor (i.e. AC) 
and 10 from control non-malignant tissue samples (NCA), as well as 10 from BC samples and 
10 from control bladder tissue (NCB) samples. Each sample was analyzed during a single 3-
hour LC-MS run, allowing the samples to be individually processed without pooling. However, 
this led to a much smaller number of only the most abundant peptides/proteins (Dataset 2 
peptides/proteins, listed in Supplementary Material Table S4) that could be quantified, as the 
information was extracted from a single LC-MS run and not from a series of LC-MS/MS runs of 
IEF sample fractions, which was the case for the pooling experiment. Nevertheless, a label-
free approach was necessary to verify whether the significance of AC vs. NC differentiation 
using VIATC peptide can be retained in a larger sample set. Using the same approach, BC 
samples were compared to non-transformed control tissue samples. We identified 126 VIATC 
consensus non-tryptic peptides in the AC/NCA dataset and 153 peptides in the BC/NCB 
dataset. The results are illustrated for 15 select peptides in Figure 7, showing significantly 
different levels in tumor samples than in controls for both AC and BC. Similar to the pooled 
experiments, peptides with a cancer-specific VIATC consensus were found in tumor samples. 
As the majority of peptides with differential expression detected in the IEF-LC-MS experiment 
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originated from the nuclear fraction, the number of VIATC differential peptides detected in 
LC-MS was relatively small. More sensitive, targeted approaches are necessary to detect 
peptides originating from low abundance proteins, bearing a more distinct cancer-specific 
signature. The number of VIATC peptides differentiating BC from NCB samples was 53 (31 
upregulated and 22 downregulated) thus, a large fraction (approximately one-third) of all 
VIATC peptides are differential for BC, i.e., either significantly overrepresented or 
underrepresented. Interestingly, several peptides were shared in the AC and BC differential 
sets (Figure 7), with a common direction of change. As such, these results reflect general 
changes in cancer tissue that are not dependent on cancer type.  However, other peptides 
were differential only in AC or BC. In general, LC-MS experiments on non-pooled sample series 
confirmed the presence of cancer-specific VIATC consensus protein fragments in both AC and 
BC tumor samples. To obtain analytical access to a panel of peptides originating from low 
abundance proteins, which could provide the most clinically relevant information, approaches 
with higher sensitivity than simple one-pass LC-MS are required.  
To verify whether our findings can be confirmed in an analysis of datasets obtained in 
other laboratories, we searched for the disease-specific VIATC consensus proteolytic 
fingerprint in datasets deposited in PRIDE (Datasets 3 &4). We analyzed 53 LC-MS raw files 
obtained from the analysis of colon cancer samples (16 AC vs. 16 controls – Dataset 3) and 
non-cancer samples originating from an analysis of mucosal colon biopsies taken by 
endoscopy from non-inflamed UC patients (10 UC vs. 10 controls – Dataset 4). For quantitation 
we used the “spectral count” approach, comparing the fraction of VIATC cleaved peptide 
queries in a given protein in disease and control groups. We detected 757 proteins 
characterized by the presence of 10 or more queries assigned to VIATC consensus cleavages 
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in the AC or control sample set. For each of these proteins, we calculated the fraction of 
queries identifying VIATC peptides compared to the total number of queries assigned to this 
protein (qVIATC/qTotal). Next, we extracted a list of 250 proteins for which qVIATC/qTotal 
was at least 2-fold larger in AC than in controls (Supplementary Material Table S5A). The 
number of proteins with the VIATC fraction underrepresented in AC by more than 2-fold was 
much smaller (Figure 8A, red marks). A similar comparison was obtained for the UC vs. control 
sample set, identifying 166 proteins with qVIATC/qTotal >2. Thus, the overrepresentation of 
VIATC cleavages in UC was also substantial. However, as Figure 8A shows, for proteins from 
the UC list the fraction of VIATC cleavages was much smaller on average than for the AC list, 
indicating markedly less frequent VIATC cleavage in UC than AC. A Venn diagram comparing 
the protein identities from the UC (Dataset 4), AC (Dataset 3), and previous iTRAQ AC analyses 
of Dataset 1 (Figure 8B) shows the number of proteins common and unique for each condition 
studied. Sixty-one of the 250 proteins identified in the PRIDE database were also identified in 
the iTRAQ experiment as being preferentially cleaved at the VIATC consensus in cancer. Forty-
nine of these proteins were not found among those preferentially cleaved in UC samples 
(Supplementary Material Table S5B). Therefore, the proteome may be affected by VIATC 
cleaving protease in a disease-specific manner.  
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Discussion 
In the course of peptide-wise proteomic analyses of AC samples, we detected abundant 
cancer-specific proteolytic events that strictly fulfill the cleavage consensus VIATC 
characteristic for neutrophil elastase. We have shown that cancer-specific elastase cleavage 
mostly affects the nuclear fraction of AC tumor tissue, with multiple RNPs affected and many 
cleavage sites localized within functionally important RRM RNA-binding domains. Differential 
peptide set linked by a common VIATC consensus was the strongest proteolytic fingerprint 
marking AC. In contrast, VIATC cleavage was not disease-dependent in TVA and TA samples. 
Other cleavage events, such as cleavage of the Asp-Gly site in keratin 18, can be detected 
much more frequently in non-cancerous tissue than in TVA, TA, or AC. In addition, multiple 
differentially proteolytic peptides with the VIATC consensus were also detected in BC samples. 
Furthermore, we confirmed our findings by analyzing cancer and UC data from the publicly 
accessible PRIDE database. 
NE, or elastase-2, is a serine protease (37) that accumulates in azurophil granules in the 
cytoplasm of neutrophils. Unlike elastase-1, NE is characterized by a well-defined narrow 
cleavage consensus. Neutrophils are a nearly exclusive source of NE and produce large 
amounts of this protease (38). Neutrophils, predominantly circulation leukocytes, are 
traditionally thought to be terminally differentiated effector cells due to their role during the 
acute phase of inflammation and host defense against pathogens. NE is able to cleave 
numerous targets, including elastin, collagens, and Omp bacterial proteins. In the traditional 
view of the role of neutrophils, the presence of the NE proteolytic signature inside tumors 
may seem to be unexpected. Protein Atlas contains IHC data for neutrophil elastase, however 
staining is negative for several CRC samples tested there. The reason could be that IHC tissue 
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arrays used in Protein Atlas are not representative to spot elastase staining which seems to 
be focal and associated with neutrophil extracellular traps (NETs) presence. In contrast to 
Protein Atlas Arelaki et al. (39) using same antibody as the one utilized in Protein Atlas (sc-
55549) have clearly shown neutrophil elastase IHC staining in CRC samples, and importantly, 
elastase presence overlapped with NETs distribution. 
The presence of NE in tumor tissues has been studied for some time (40), (41), also in 
the context of breast cancer (42). Its  potential prognostic value was also assessed (43), (44), 
(45). A role of protease-inhibitor imbalance in cancer progression has been suggested (46), and 
NE has been proposed as a new therapeutic target (47), (48), (49), (50). For many cancer types, 
increased NE presence has been correlated with cancer stage, grade, and survival. Currently, 
the discussion focuses on the prognostic relevance of tumor-associated neutrophils (51) and 
their anti-tumor and pro-tumor activities (52), (53), which are most likely connected to the 
neutrophil maturation pathway (54). Similar to macrophages, neutrophils infiltrate tumors, 
but their role in the modification of cancer progression has just begun to emerge (47), (55). 
These cells are a major source of stromal proteases in tumors, and elastase secreted by 
neutrophils has been shown to be taken up into lung and breast cancer cells (56) via an 
endocytic, clathrin-mediated pathway (42), (57). Neutrophil infiltration was found to be 
gradually reduced from the tumor mass to the distal margin (39). However, the presence of 
neutrophils in tumors is not sufficient to explain the observation that a large set of nuclear 
proteins is also affected. Apoptotic tumor cells may provide nuclear proteins for elastase 
cleavage, or NE proteolytic fragments of nuclear proteins may be neutrophil proteins 
degraded during NET-osis (58), a neutrophil-specific process of controlled cell death during 
which extruded fibrillary networks composed of nuclear components and granule proteins, 
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the so called neutrophil extracellular traps, are formed (59). Thus, during the course of NET-
osis, the nuclear envelope disintegrates, granting access to its nuclear proteins. NET-osis has 
been detected in tumors (60), and a causative link between NET formation and cancer-
associated thrombosis, one of the major causes of death in cancer patients, has been 
established (61). Moreover, proteomic analysis of NET-associated substrate profiles indicates 
a predominant contribution by NE (62). Irrelevant if their source are tumor cells or neutrophils 
elastase-cleaved peptides mark the tumor presence. 
Many other non-caspase proteases have emerged as active players in apoptotic 
proteolytic cascades (1), (63). These proteases can target proteins that are not cleaved by 
caspases (64) or the same proteins. Many proteins found in the present study to be cleaved at 
VIATC consensus are also known to be cleaved by caspases (e.g. keratin 18, nucleolin, 
vimentin, lamin B2, annexins, alpha-actinin, gelsolin, hnRNPs, ribosomal proteins, elongation 
factors; Table 2 in (65), Table 1 in (66)). 111 proteins containing VIATC peptides characterized 
by a large AC/NC ratio in our study are also present on the list of caspase targets compiled 
recently (see Tables S2 and S4 in (67)). Thus, ca. 25% of the proteins found in our study are 
known caspase targets. Notably, a large fraction of proteins modified in apoptosis contain 
RNA-binding motifs, including RRM domains (66), (68), (69), similar to the overrepresentation 
of RNPs in the VIATC protein set with a preference for cleavage at RRM domains.  
Currently, the most widespread protein fragments used for cancer studies originate 
from caspase cleavage of keratins. TPA is a protein antigen that was identified in 1957 by 
raising antibodies against pooled tumors. TPA has been identified as consisting of keratins 8, 
18, and 19 and/or their fragments (70). TPA reactivity is derived from specific epitopes of 
human cytokeratin 18, mainly fragment 284-396 (71). In keratin 18 the so-called M30 epitope 
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comes from a >20 kDa keratin fragment resulting from two caspase cleavages at sequence 
consensus sites V235EVD and D394ALD (7). The target sites for the keratin 19-derived Cyfra 21-
1 monoclonal antibodies BM 19.21 and KS 19.1 lie within amino acids 346–367 and amino 
acids 311–335, respectively. These mAbs detect a keratin 19 fragment most likely resulting 
from cleavage at caspase site S233VEVD (72) in the helix 2B region of the rod domain of keratin 
19. The Cyfra 21-1 assay has found broad clinical application, allowing the monitoring of 
treatment and the response to therapy, and has proven to be particularly useful in the case of 
squamous cell carcinomas of the lung (6). However, some authors have found that these 
antibodies detect intact keratin 19 instead of the Cyfra 21-1 fragment (73). A more detailed 
comparison of fragment-specific and total keratin 18 antibodies has been carried out in the 
context of lung cancer (74).  
NE has not previously been mentioned in the context of non-caspase proteases 
involved in mediating/promoting cell death; nevertheless, its secondary role cannot be 
excluded as the VIATC P1 cleavage was the strongest cancer-specific proteolytic fingerprint 
that could be detected in cancer tissues. Proteolytic cleavage is not only a simple degradation 
event, but also an important signaling event (75). Thus, we can reasonably expect that 
proteolytic fingerprints reflect important processes, including cancer development, and can 
be a source of biomarker panels. Neutrophil-specific elastase cleavage may be of value, as the 
presence of tumor-infiltrating neutrophils often correlates with clinical outcome.  
A 2002 paper claiming an efficient SELDI-based ovarian cancer biomarker serum panel 
offered high hopes for efficient biomarkers (76). However, further work dampened the initial 
optimism, providing knowledge on multiple factors that mask disease-related changes in the 
proteome of biofluids  (77), (78) and the successes are currently very limited (79). To overcome 
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these problems, more targeted approaches coupled with new high-confidence MS methods 
are necessary. Jimenez et al. (80) summarized this well: “We anticipate that in the near future, 
these novel mass spectrometry-based in-depth approaches will uncover many novel, specific 
CRC marker candidates in clinical tissues and that their targeted validation with multi-reaction 
monitoring MS will speed up development of non-invasive tests in feces and serum/plasma.”  
In conclusion, during the course of global analyses of cancer vs. control tissue samples, 
we detected a very strong cancer-specific proteolytic fingerprint of non-tryptic cleavages. 
Proteomic experiments on both colon and bladder tumor tissue indicated the presence of 
numerous proteolytic protein fragments, whose abundance strongly correlated with the 
presence of cancer. We noted a significant number of differential peptides characterized by 
VIATC consensus cleavage sites. As outliers in the protein-wise analysis, these peptides are 
usually ignored during routine global differential proteomics, but they may provide important 
information on disease-related proteolytic events. Currently, only a few protein fragments are 
the object of more detailed tests exploring their diagnostic/prognostic potential, but our work 
shows that the spectrum of possible cancer-specific peptide markers may be much broader. 
Similar to caspase-derived keratin fragments, elastase- and/or meprin-derived peptides can 
be released into the circulation during cellular breakdown and be detected by sensitive 
enough methods. The newly detected fragments, bearing the strict fingerprint of elastase 
cleavage specificity, in our opinion most likely originate from the activity of neutrophil elastase 
infiltrating tumors, which is a not-unexpected well known phenomenon. The substrate 
proteins may originate from the tumor cells, and/or neutrophil cells undergoing netosis. While 
we do not speculate what is the major source of substrates we identify, we conclude that their 
presence is strongly correlated with tumor presence, providing a source of potential disease 
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markers. We are aware that the identification of a marker is merely a small initial step towards 
diagnosis, early detection, prognosis or personalization of the treatment and the ultimate 
tests should be carried out on body fluids, preferably plasma/serum samples. However, we 
believe that the direct detection of highly diluted peptide fragments in plasma/serum, without 
prior enrichment, is not possible with the present state of the art LC-MS systems. We also 
believe that enrichment strategies when worked out and optimized will enable such detection 
and quantification of low abundance fragments, as was already shown by numerous examples 
(81), (82).  
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Figure and Table Legends 
Table 1. Four types of datasets analyzed in this work, along with source of dataset, number of 
samples, quantitation method and search engine used. 
 
Scheme 1. A flowchart explaining the data analysis approaches used for each of the Datasets 
1-4. 
 
Figure 1. (A) Adenocarcinoma (AC)/non-cancer (NC) ratio of different peptides originating 
from keratin 18 and (B) keratin 8. Peptides are shown as black bars positioned at their 
corresponding location in sequence at the horizontal axis. Error bars are standard deviation of 
three independent experiments. Lack of an error bar indicates that a peptide was detected in 
one of the three experiments. Non-tryptic cleavages are marked by color circles, either N-
terminal (red) or C-terminal (blue). Arrows indicate the positions of non-tryptic cleavage of 
the highest AC/NC ratio in protein regions. 
 
Figure 2. Box-plots correlating the adenocarcinoma (AC)/non-cancer (NC) ratio and nature of 
the cleavage site with P2’-P2 positions based on the analysis of 17 965 iTRAQ-labeled 
peptides. Boxes denote interquartile range while whiskers extend to the most extreme data 
point which is no more than 1.5 times the interquartile range from the box. Asterisks denote 
p-value < 10-6. A significant cancer-dependent shift in the AC/NC ratio is prominent if the P1 
position is Val, Ile, Thr, Ala, or Cys. 
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Figure 3. STRING analysis of proteins cleaved by neutrophil elastase in a cancer-specific 
manner. Adjusted p-values calculated by STRING are provided for significantly 
overrepresented groups of proteins. 
 
Figure 4. (A) Numbers of total tryptic peptides and VIATC consensus peptides detected in four 
fractions: cytoskeletal, cytoplasmic, membrane+ organelle, and nuclear. (B) Box-plots of 
adenocarcinoma (AC)/non-cancer (NC) ratios for VIATC consensus peptide abundance in four 
fractions on the logarithmic scale. Boxes denote interquartile range while whiskers extend to 
the most extreme data point which is no more than 1.5 times the interquartile range from the 
box. VIATC peptides were significantly more abundant in AC only for the nuclear fraction, 
indicating that the majority of VIATC nuclear peptides are overrepresented in colon cancer 
tissue. 
 
Figure 5. (A) Box-plots correlating FC values for VIATC consensus cleaved peptides and all other 
peptides when tubulo-villous adenoma (TVA - iTRAQ115), tubular adenoma (TA – iTRAQ116), 
and adenocarcinoma (AC – iTRAQ117) samples were compared to normal tissue (NC – 
iTRAQ114). Boxes denote interquartile range while whiskers extend to the most extreme data 
point which is no more than 1.5 times the interquartile range from the box. Only in AC an 
increased abundance of VIATC peptides is observed, as compared to NC. (B) Principal 
component analysis based on a set of VIATC consensus cleaved peptides shows a good 
separation of NC, TVA, TA, and AC groups. The first component separated AC from NC best, 
whereas the second component separated TVA/TA from NC. 
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Figure 6. Principal component analysis of AC – iTRAQ117, TVA – iTRAQ115, TA – iTRAQ116, 
and NC – iTRAQ114 in triplicate based on the abundance of non-tryptic peptides. 
 
Figure 7. Non-pooled sample series analysis of 10 adenocarcinoma (AC) samples and 10 
bladder cancer (BC) samples. Box-plots representing peptide abundance for AC vs. control 
samples (NCA) and BC vs. control tissue (NCB) for selected VIATC consensus peptides. Boxes 
denote interquartile range while whiskers extend to the most extreme data point which is no 
more than 1.5 times the interquartile range from the box. Asterisks denote * - q<0.05, ** - 
q<0.01. 
 
Figure 8. (A) Fraction of queries assigned to VIATC peptides (qVIATC/qTotal) for a subset of 
PRIDE database proteins in disease (vertical axis) and control samples (horizontal axis) for 
adenocarcinoma (AC; red) and ulcerative colitis (UC; blue). Data for proteins characterized by 
the presence of more than 10 VIATC queries are shown. For clarity, data from proteins with a 
qVIATC/qTotal between 0.5 and 2 are not shown. Proteins marked on the vertical axis had no 
VIATC queries in control samples, whereas proteins marked on the horizontal axis had no 
VIATC queries in disease samples. Note the higher number of proteins with qVIATC/qTotal >2 
(placed above the diagonal) than qVIATC/qTotal <0.5 (placed below the diagonal) in disease 
samples, both AC and UC. Also note the significantly lower average fraction of VIATC cleavages 
in UC than AC. (B) Venn diagram illustrating number of common and unique proteins 
containing significantly overrepresented VIATC-cleaved peptides in iTRAQ adenocarcinoma, 
PRIDE adenocarcinoma and PRIDE ulcerative colitis dataset. Note 49 proteins commonly 
identified in iTRAQ and PRIDE adenocarcinoma dataset and absent in ulcerative colitis dataset. 
Dataset Tissue type Reanalysis? Source Num. of samples Pooled? Quantitation Search engine 
        
Dataset 1 colon cancer yes 
Previously published data (17) 
PXD005274 
3 AC 
3 TVA 
3 TA 
3 NC 
yes iTRAQ Mascot 
Dataset 2 colon cancer  Experimental data 
10 AC 
10 NC    
 
bladder cancer no PXD004249 10 BC 
10 NC 
no label-free Mascot 
Dataset 3 colorectal cancer yes PRIDE (PXD002041-2050) 
16 AC 
16 NC 
no spectral count MS-GF+ 
Dataset 4 ulcerative colitis yes PRIDE (PXD001608) 
10 UC 
10 NC 
no spectral count MS-GF+ 
 
Table 1 
  
 
 
 
 
 
 
Scheme 1 
Dataset 1 Dataset 2 Dataset  3, 4 
MASCOT MASCOT MS-GF+ Search engine 
Quantitation method iTRAQ Label-free Spectral count 
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